- Home
- CB vs REGN Comparison
CB vs REGN Comparison
Compare CB & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- REGN
- Stock Information
- Founded
- CB 1985
- REGN 1988
- Country
- CB Switzerland
- REGN United States
- Employees
- CB N/A
- REGN N/A
- Industry
- CB Property-Casualty Insurers
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- CB Finance
- REGN Health Care
- Exchange
- CB Nasdaq
- REGN Nasdaq
- Market Cap
- CB 114.8B
- REGN 110.0B
- IPO Year
- CB 1993
- REGN 1991
- Fundamental
- Price
- CB $292.33
- REGN $639.06
- Analyst Decision
- CB Buy
- REGN Buy
- Analyst Count
- CB 16
- REGN 25
- Target Price
- CB $301.13
- REGN $990.84
- AVG Volume (30 Days)
- CB 2.0M
- REGN 948.2K
- Earning Date
- CB 04-22-2025
- REGN 05-01-2025
- Dividend Yield
- CB 1.25%
- REGN 0.14%
- EPS Growth
- CB 4.13
- REGN 10.27
- EPS
- CB 22.70
- REGN 38.34
- Revenue
- CB $55,882,000,000.00
- REGN $14,202,000,000.00
- Revenue This Year
- CB N/A
- REGN $4.75
- Revenue Next Year
- CB $5.52
- REGN $5.70
- P/E Ratio
- CB $12.84
- REGN $16.54
- Revenue Growth
- CB 12.45
- REGN 8.27
- 52 Week Low
- CB $238.85
- REGN $633.17
- 52 Week High
- CB $302.05
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- CB 58.45
- REGN 41.65
- Support Level
- CB $289.22
- REGN $651.06
- Resistance Level
- CB $299.33
- REGN $667.46
- Average True Range (ATR)
- CB 5.45
- REGN 20.83
- MACD
- CB -0.32
- REGN -3.69
- Stochastic Oscillator
- CB 61.89
- REGN 9.19
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).